JCEM:子痫前期患者中,多种可溶性TGF-β受体协同抑制TGF-β信号通路

2017-06-30 MedSci MedSci原创

怀孕前血压正常的孕妇在妊娠20周以后出现高血压、蛋白尿,称子痫前期,或称为先兆子痫。是妊娠期高血压疾病的五种状况之一,为妊娠期特发疾病,可影响机体各器官系统。发病率约占全部妊娠的3.9%。子痫前期(Preeclampsia,PE)可分为早发型(妊娠<34周)和迟发型(妊娠> 34周)两个亚型。与子痫前期发病相关的重要机制包括:血管痉挛、内皮细胞激活、升压反应增加、前列腺素、一氧化氮、内皮素和

怀孕前血压正常的孕妇在妊娠20周以后出现高血压、蛋白尿,称子痫前期,或称为先兆子痫。是妊娠期高血压疾病的五种状况之一,为妊娠期特发疾病,可影响机体各器官系统。发病率约占全部妊娠的3.9%。子痫前期(Preeclampsia,PE)可分为早发型(妊娠<34周)和迟发型(妊娠> 34周)两个亚型。

与子痫前期发病相关的重要机制包括:血管痉挛、内皮细胞激活、升压反应增加、前列腺素、一氧化氮、内皮素和血管生成和抗血管生成的蛋白质。可溶性内皮抑素,是一种辅助受体作用于TGF-β配体,在PE循环中增加,且被认为能与配体结合形成隔离抑制TGF-β通过。然而,可溶性内皮抑素,与TGF-β配体的亲和力较低,已被证明对TGF-β活动的影响并不大。6月发表在JCEM上的一项研究中,研究人员探究了PE循环中多种可溶性TGF-β受体水平是否有升高,以及它们是否协同阻断TGF-β信号转导。

使用ELISA法检测在先兆子痫妊娠和妊娠年龄匹配的对照组的血清中检测TGF-β受体。用体外生物测定和试管形成试验评估TGF-β信号

妊娠期血清中均检测到TGF-βI、II和III受体,在早发型PE中均显著升高,但迟发型PE中未升高。在所有类型的PE中内皮抑素均增加。在PE中检测到最高浓度,这些可溶性TGF-β受体没有独自出现,包括:内皮抑素,抑制性TGF-β信号。然而,当所有四个可溶性受体都存在时,TGF-β1和TGF-β2的信号显著减少。去除可溶性受体减轻TGF-β1抑制,但去除可溶性TGF-βRIII时减轻TGF-β2抑制。

多种可溶性TGF-β受体存在于妊娠期血循环中,这些受体在早发型PE中升高,它们协同抑制TGF-β信号,且这种抑制作用在早发型比晚发型PE中更可能发生。减少可溶性TGF-βRIII比内皮抑素会更有效地缓解TGF-β1和TGF-β2信号的抑制情况。

原始出处:

Wang Y, Chen Q,et al.Multiple soluble TGF-β receptors in addition to soluble endoglin are elevated in preeclamptic serum and they synergistically inhibit TGF-β signalling.J Clin Endocrinol Metab. 2017 Jun 14. doi: 10.1210/jc.2017-01150. [Epub ahead of print]

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (7)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1777620, encodeId=1db51e776207c, content=<a href='/topic/show?id=eb9610265ed' target=_blank style='color:#2F92EE;'>#JCEM#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10265, encryptionId=eb9610265ed, topicName=JCEM)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2a4439169927, createdName=smallant2015, createdTime=Fri Dec 08 08:27:00 CST 2017, time=2017-12-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2035848, encodeId=7d46203584834, content=<a href='/topic/show?id=575c1e341a8' target=_blank style='color:#2F92EE;'>#TGF#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17341, encryptionId=575c1e341a8, topicName=TGF)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=56ea361, createdName=changhe713, createdTime=Sun Aug 06 21:27:00 CST 2017, time=2017-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2063002, encodeId=2d4520630027f, content=<a href='/topic/show?id=14fb10264d7' target=_blank style='color:#2F92EE;'>#JCE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10264, encryptionId=14fb10264d7, topicName=JCE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e656479, createdName=achengzhao, createdTime=Thu Aug 03 11:27:00 CST 2017, time=2017-08-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=218796, encodeId=723e218e96c0, content=继续关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=93f31631454, createdName=1dd8c52fm63(暂无匿称), createdTime=Wed Jul 05 12:00:59 CST 2017, time=2017-07-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1366554, encodeId=08fb136655475, content=<a href='/topic/show?id=097a452219b' target=_blank style='color:#2F92EE;'>#子痫前期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45221, encryptionId=097a452219b, topicName=子痫前期)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=52c7237, createdName=yahu, createdTime=Sun Jul 02 13:27:00 CST 2017, time=2017-07-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1441352, encodeId=ac4a14413526a, content=<a href='/topic/show?id=58dd1e34591' target=_blank style='color:#2F92EE;'>#TGF-β#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17345, encryptionId=58dd1e34591, topicName=TGF-β)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Sun Jul 02 13:27:00 CST 2017, time=2017-07-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1539612, encodeId=e727153961294, content=<a href='/topic/show?id=c61a2e315da' target=_blank style='color:#2F92EE;'>#信号通路#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=27315, encryptionId=c61a2e315da, topicName=信号通路)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=智者为医08, createdTime=Sun Jul 02 13:27:00 CST 2017, time=2017-07-02, status=1, ipAttribution=)]
    2017-12-08 smallant2015
  2. [GetPortalCommentsPageByObjectIdResponse(id=1777620, encodeId=1db51e776207c, content=<a href='/topic/show?id=eb9610265ed' target=_blank style='color:#2F92EE;'>#JCEM#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10265, encryptionId=eb9610265ed, topicName=JCEM)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2a4439169927, createdName=smallant2015, createdTime=Fri Dec 08 08:27:00 CST 2017, time=2017-12-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2035848, encodeId=7d46203584834, content=<a href='/topic/show?id=575c1e341a8' target=_blank style='color:#2F92EE;'>#TGF#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17341, encryptionId=575c1e341a8, topicName=TGF)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=56ea361, createdName=changhe713, createdTime=Sun Aug 06 21:27:00 CST 2017, time=2017-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2063002, encodeId=2d4520630027f, content=<a href='/topic/show?id=14fb10264d7' target=_blank style='color:#2F92EE;'>#JCE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10264, encryptionId=14fb10264d7, topicName=JCE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e656479, createdName=achengzhao, createdTime=Thu Aug 03 11:27:00 CST 2017, time=2017-08-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=218796, encodeId=723e218e96c0, content=继续关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=93f31631454, createdName=1dd8c52fm63(暂无匿称), createdTime=Wed Jul 05 12:00:59 CST 2017, time=2017-07-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1366554, encodeId=08fb136655475, content=<a href='/topic/show?id=097a452219b' target=_blank style='color:#2F92EE;'>#子痫前期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45221, encryptionId=097a452219b, topicName=子痫前期)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=52c7237, createdName=yahu, createdTime=Sun Jul 02 13:27:00 CST 2017, time=2017-07-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1441352, encodeId=ac4a14413526a, content=<a href='/topic/show?id=58dd1e34591' target=_blank style='color:#2F92EE;'>#TGF-β#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17345, encryptionId=58dd1e34591, topicName=TGF-β)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Sun Jul 02 13:27:00 CST 2017, time=2017-07-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1539612, encodeId=e727153961294, content=<a href='/topic/show?id=c61a2e315da' target=_blank style='color:#2F92EE;'>#信号通路#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=27315, encryptionId=c61a2e315da, topicName=信号通路)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=智者为医08, createdTime=Sun Jul 02 13:27:00 CST 2017, time=2017-07-02, status=1, ipAttribution=)]
    2017-08-06 changhe713
  3. [GetPortalCommentsPageByObjectIdResponse(id=1777620, encodeId=1db51e776207c, content=<a href='/topic/show?id=eb9610265ed' target=_blank style='color:#2F92EE;'>#JCEM#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10265, encryptionId=eb9610265ed, topicName=JCEM)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2a4439169927, createdName=smallant2015, createdTime=Fri Dec 08 08:27:00 CST 2017, time=2017-12-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2035848, encodeId=7d46203584834, content=<a href='/topic/show?id=575c1e341a8' target=_blank style='color:#2F92EE;'>#TGF#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17341, encryptionId=575c1e341a8, topicName=TGF)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=56ea361, createdName=changhe713, createdTime=Sun Aug 06 21:27:00 CST 2017, time=2017-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2063002, encodeId=2d4520630027f, content=<a href='/topic/show?id=14fb10264d7' target=_blank style='color:#2F92EE;'>#JCE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10264, encryptionId=14fb10264d7, topicName=JCE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e656479, createdName=achengzhao, createdTime=Thu Aug 03 11:27:00 CST 2017, time=2017-08-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=218796, encodeId=723e218e96c0, content=继续关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=93f31631454, createdName=1dd8c52fm63(暂无匿称), createdTime=Wed Jul 05 12:00:59 CST 2017, time=2017-07-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1366554, encodeId=08fb136655475, content=<a href='/topic/show?id=097a452219b' target=_blank style='color:#2F92EE;'>#子痫前期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45221, encryptionId=097a452219b, topicName=子痫前期)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=52c7237, createdName=yahu, createdTime=Sun Jul 02 13:27:00 CST 2017, time=2017-07-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1441352, encodeId=ac4a14413526a, content=<a href='/topic/show?id=58dd1e34591' target=_blank style='color:#2F92EE;'>#TGF-β#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17345, encryptionId=58dd1e34591, topicName=TGF-β)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Sun Jul 02 13:27:00 CST 2017, time=2017-07-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1539612, encodeId=e727153961294, content=<a href='/topic/show?id=c61a2e315da' target=_blank style='color:#2F92EE;'>#信号通路#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=27315, encryptionId=c61a2e315da, topicName=信号通路)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=智者为医08, createdTime=Sun Jul 02 13:27:00 CST 2017, time=2017-07-02, status=1, ipAttribution=)]
    2017-08-03 achengzhao
  4. [GetPortalCommentsPageByObjectIdResponse(id=1777620, encodeId=1db51e776207c, content=<a href='/topic/show?id=eb9610265ed' target=_blank style='color:#2F92EE;'>#JCEM#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10265, encryptionId=eb9610265ed, topicName=JCEM)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2a4439169927, createdName=smallant2015, createdTime=Fri Dec 08 08:27:00 CST 2017, time=2017-12-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2035848, encodeId=7d46203584834, content=<a href='/topic/show?id=575c1e341a8' target=_blank style='color:#2F92EE;'>#TGF#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17341, encryptionId=575c1e341a8, topicName=TGF)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=56ea361, createdName=changhe713, createdTime=Sun Aug 06 21:27:00 CST 2017, time=2017-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2063002, encodeId=2d4520630027f, content=<a href='/topic/show?id=14fb10264d7' target=_blank style='color:#2F92EE;'>#JCE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10264, encryptionId=14fb10264d7, topicName=JCE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e656479, createdName=achengzhao, createdTime=Thu Aug 03 11:27:00 CST 2017, time=2017-08-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=218796, encodeId=723e218e96c0, content=继续关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=93f31631454, createdName=1dd8c52fm63(暂无匿称), createdTime=Wed Jul 05 12:00:59 CST 2017, time=2017-07-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1366554, encodeId=08fb136655475, content=<a href='/topic/show?id=097a452219b' target=_blank style='color:#2F92EE;'>#子痫前期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45221, encryptionId=097a452219b, topicName=子痫前期)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=52c7237, createdName=yahu, createdTime=Sun Jul 02 13:27:00 CST 2017, time=2017-07-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1441352, encodeId=ac4a14413526a, content=<a href='/topic/show?id=58dd1e34591' target=_blank style='color:#2F92EE;'>#TGF-β#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17345, encryptionId=58dd1e34591, topicName=TGF-β)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Sun Jul 02 13:27:00 CST 2017, time=2017-07-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1539612, encodeId=e727153961294, content=<a href='/topic/show?id=c61a2e315da' target=_blank style='color:#2F92EE;'>#信号通路#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=27315, encryptionId=c61a2e315da, topicName=信号通路)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=智者为医08, createdTime=Sun Jul 02 13:27:00 CST 2017, time=2017-07-02, status=1, ipAttribution=)]
    2017-07-05 1dd8c52fm63(暂无匿称)

    继续关注

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1777620, encodeId=1db51e776207c, content=<a href='/topic/show?id=eb9610265ed' target=_blank style='color:#2F92EE;'>#JCEM#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10265, encryptionId=eb9610265ed, topicName=JCEM)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2a4439169927, createdName=smallant2015, createdTime=Fri Dec 08 08:27:00 CST 2017, time=2017-12-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2035848, encodeId=7d46203584834, content=<a href='/topic/show?id=575c1e341a8' target=_blank style='color:#2F92EE;'>#TGF#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17341, encryptionId=575c1e341a8, topicName=TGF)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=56ea361, createdName=changhe713, createdTime=Sun Aug 06 21:27:00 CST 2017, time=2017-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2063002, encodeId=2d4520630027f, content=<a href='/topic/show?id=14fb10264d7' target=_blank style='color:#2F92EE;'>#JCE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10264, encryptionId=14fb10264d7, topicName=JCE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e656479, createdName=achengzhao, createdTime=Thu Aug 03 11:27:00 CST 2017, time=2017-08-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=218796, encodeId=723e218e96c0, content=继续关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=93f31631454, createdName=1dd8c52fm63(暂无匿称), createdTime=Wed Jul 05 12:00:59 CST 2017, time=2017-07-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1366554, encodeId=08fb136655475, content=<a href='/topic/show?id=097a452219b' target=_blank style='color:#2F92EE;'>#子痫前期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45221, encryptionId=097a452219b, topicName=子痫前期)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=52c7237, createdName=yahu, createdTime=Sun Jul 02 13:27:00 CST 2017, time=2017-07-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1441352, encodeId=ac4a14413526a, content=<a href='/topic/show?id=58dd1e34591' target=_blank style='color:#2F92EE;'>#TGF-β#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17345, encryptionId=58dd1e34591, topicName=TGF-β)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Sun Jul 02 13:27:00 CST 2017, time=2017-07-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1539612, encodeId=e727153961294, content=<a href='/topic/show?id=c61a2e315da' target=_blank style='color:#2F92EE;'>#信号通路#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=27315, encryptionId=c61a2e315da, topicName=信号通路)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=智者为医08, createdTime=Sun Jul 02 13:27:00 CST 2017, time=2017-07-02, status=1, ipAttribution=)]
    2017-07-02 yahu
  6. [GetPortalCommentsPageByObjectIdResponse(id=1777620, encodeId=1db51e776207c, content=<a href='/topic/show?id=eb9610265ed' target=_blank style='color:#2F92EE;'>#JCEM#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10265, encryptionId=eb9610265ed, topicName=JCEM)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2a4439169927, createdName=smallant2015, createdTime=Fri Dec 08 08:27:00 CST 2017, time=2017-12-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2035848, encodeId=7d46203584834, content=<a href='/topic/show?id=575c1e341a8' target=_blank style='color:#2F92EE;'>#TGF#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17341, encryptionId=575c1e341a8, topicName=TGF)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=56ea361, createdName=changhe713, createdTime=Sun Aug 06 21:27:00 CST 2017, time=2017-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2063002, encodeId=2d4520630027f, content=<a href='/topic/show?id=14fb10264d7' target=_blank style='color:#2F92EE;'>#JCE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10264, encryptionId=14fb10264d7, topicName=JCE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e656479, createdName=achengzhao, createdTime=Thu Aug 03 11:27:00 CST 2017, time=2017-08-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=218796, encodeId=723e218e96c0, content=继续关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=93f31631454, createdName=1dd8c52fm63(暂无匿称), createdTime=Wed Jul 05 12:00:59 CST 2017, time=2017-07-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1366554, encodeId=08fb136655475, content=<a href='/topic/show?id=097a452219b' target=_blank style='color:#2F92EE;'>#子痫前期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45221, encryptionId=097a452219b, topicName=子痫前期)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=52c7237, createdName=yahu, createdTime=Sun Jul 02 13:27:00 CST 2017, time=2017-07-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1441352, encodeId=ac4a14413526a, content=<a href='/topic/show?id=58dd1e34591' target=_blank style='color:#2F92EE;'>#TGF-β#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17345, encryptionId=58dd1e34591, topicName=TGF-β)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Sun Jul 02 13:27:00 CST 2017, time=2017-07-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1539612, encodeId=e727153961294, content=<a href='/topic/show?id=c61a2e315da' target=_blank style='color:#2F92EE;'>#信号通路#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=27315, encryptionId=c61a2e315da, topicName=信号通路)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=智者为医08, createdTime=Sun Jul 02 13:27:00 CST 2017, time=2017-07-02, status=1, ipAttribution=)]
    2017-07-02 zhaojie88
  7. [GetPortalCommentsPageByObjectIdResponse(id=1777620, encodeId=1db51e776207c, content=<a href='/topic/show?id=eb9610265ed' target=_blank style='color:#2F92EE;'>#JCEM#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10265, encryptionId=eb9610265ed, topicName=JCEM)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2a4439169927, createdName=smallant2015, createdTime=Fri Dec 08 08:27:00 CST 2017, time=2017-12-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2035848, encodeId=7d46203584834, content=<a href='/topic/show?id=575c1e341a8' target=_blank style='color:#2F92EE;'>#TGF#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17341, encryptionId=575c1e341a8, topicName=TGF)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=56ea361, createdName=changhe713, createdTime=Sun Aug 06 21:27:00 CST 2017, time=2017-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2063002, encodeId=2d4520630027f, content=<a href='/topic/show?id=14fb10264d7' target=_blank style='color:#2F92EE;'>#JCE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10264, encryptionId=14fb10264d7, topicName=JCE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e656479, createdName=achengzhao, createdTime=Thu Aug 03 11:27:00 CST 2017, time=2017-08-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=218796, encodeId=723e218e96c0, content=继续关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=93f31631454, createdName=1dd8c52fm63(暂无匿称), createdTime=Wed Jul 05 12:00:59 CST 2017, time=2017-07-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1366554, encodeId=08fb136655475, content=<a href='/topic/show?id=097a452219b' target=_blank style='color:#2F92EE;'>#子痫前期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45221, encryptionId=097a452219b, topicName=子痫前期)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=52c7237, createdName=yahu, createdTime=Sun Jul 02 13:27:00 CST 2017, time=2017-07-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1441352, encodeId=ac4a14413526a, content=<a href='/topic/show?id=58dd1e34591' target=_blank style='color:#2F92EE;'>#TGF-β#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17345, encryptionId=58dd1e34591, topicName=TGF-β)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Sun Jul 02 13:27:00 CST 2017, time=2017-07-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1539612, encodeId=e727153961294, content=<a href='/topic/show?id=c61a2e315da' target=_blank style='color:#2F92EE;'>#信号通路#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=27315, encryptionId=c61a2e315da, topicName=信号通路)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=智者为医08, createdTime=Sun Jul 02 13:27:00 CST 2017, time=2017-07-02, status=1, ipAttribution=)]

相关资讯

JCEM:外泌体miRNA或是子痫前期的生物标志物

子痫前期(preeclampsia,PE,又称为先兆子痫)的发生率大约为3~5%,并不少见,是妊娠特发性疾病,高危因素有很多,但如果发现得早是完全可以治疗的。因此,制定早期预测子痫前期的策略是必要的,以制定PE预防策略,进而减少疾病的发生率和相关并发症,及减轻疾病的严重程度。来自澳大利亚昆士兰大学的研究人员探讨了母体循环中外泌体及其microRNA是否可以作为PE的早期生物标志物。本研究是一个回顾

Lancet:米索前列醇用于子痫前期以及高血压产妇催产

子痫前期以及高血压产妇,口服米索前列醇是有效的催产方法

Circ-Heart Fail:子痫前期对围产期心肌病妇女的临床和功能结局的影响如何?

由此可见,相比于不伴有子痫前期的PPCM患者,PPCM合并子痫前期与发病率和死亡率增加相关,并且与不同的LV重构模式以及左室功能恢复相关。

USPSTF呼吁:常规化孕期子痫前期筛查

美国预防服务工作组(USPSTF)对之前发布的声明草案进行了重申:呼吁孕期常规进行子痫前期的筛查。 关于血压测量对孕妇子痫前期筛查的益处,得到了机构的“适度”的肯定,推荐等级为B。 在对子痫前期检测方式进行评估时,USPSTF认为有足够的证据支持血压测量的准确度;此外,还有足够的证据表明,蛋白尿检测时,使用试纸测试尿蛋白的诊断准确率低。 在评估早期检测和治疗子痫前期的利弊时,有足

Obstet Gynecol:子痫前期孕妇更容易发生视网膜疾病

子痫前期,特别严重的或是早发型子痫前期、妊娠后几十年母亲视网膜疾病发生高风险相关。

Hypertension:sFlt-1:PLGF比值可用来预测孕妇子痫前期风险

sFlt-1:PLGF比值为未经选择的单胎妊娠初产妇出现子痫前期最重要的临床表现的预测提供了有用的临床风险预测指标。